ONCE Spark Therapeutics Inc.

100.12
+1.04  (+1%)
Previous Close 99.08
Open 98.8
Price To Book 9.59
Market Cap 3,853,244,151
Shares 38,486,258
Volume 392,948
Short Ratio
Av. Daily Volume 433,976
Stock charts supplied by TradingView

NewsSee all news

  1. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all

  2. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 30 September 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  3. Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing

    Paralympic, blind skier declared Eye Want 2 Know® and pursued genetic testing to uncover the genetic cause of her retinitis pigmentosa (RP), an IRD Spark Therapeutics unveils enhanced ID YOUR IRD® genetic test for

  4. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 3 September 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  5. Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

    PHILADELPHIA, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial commenced early 2019.
SPK-8011
Hemophilia A
Phase 1/2 updated data released May 22, 2018 - 98% decrease in bleeding rate.
SPK-9001
Hemophilia B
Phase 1/2 ongoing.
SPK-7001 (SPK-CHM)
Choroideremia
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval. Approval announced December 19, 2017.
Luxturna (voretigene neparvovec)
Inherited retinal dystrophies
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B

Latest News

  1. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all

  2. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 30 September 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  3. Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing

    Paralympic, blind skier declared Eye Want 2 Know® and pursued genetic testing to uncover the genetic cause of her retinitis pigmentosa (RP), an IRD Spark Therapeutics unveils enhanced ID YOUR IRD® genetic test for

  4. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 3 September 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  5. Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

    PHILADELPHIA, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the